Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Anton Camaj, Michael S. Miller, Jonathan L. Halperin, Gennaro Giustino

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Patients with atrial fibrillation who undergo percutaneous coronary intervention with drug-eluting stent implantation often require oral anticoagulation (OAC) and antiplatelet therapies. Triple antithrombotic therapy (OAC, a P2Y12-receptor inhibitor, and aspirin) has been the default antithrombotic strategy. Evidence from randomized trials indicates, however, that a dual antithrombotic therapy strategy (OAC plus a P2Y12-receptor inhibitor) reduces bleeding risk without increasing the risk of ischemic events. This review provides an overview of advancements in this field as well as European and North American guidelines and consensus documents to inform clinical decision making around antithrombotic therapies for patients with atrial fibrillation who undergo percutaneous coronary intervention.

Original languageEnglish
Pages (from-to)551-561
Number of pages11
JournalCardiology Clinics
Volume38
Issue number4
DOIs
StatePublished - Nov 2020

Keywords

  • Atrial fibrillation
  • Dual antithrombotic therapy
  • Percutaneous coronary intervention
  • Triple antithrombotic therapy

Fingerprint

Dive into the research topics of 'Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention'. Together they form a unique fingerprint.

Cite this